Taysha Gene Therapies, Inc. 8-K

What Happened
Taysha Gene Therapies, Inc. announced financial results for the year ended December 31, 2025 in an 8-K filed March 19, 2026. The company furnished a press release with those results and recent business highlights as Exhibit 99.1 to the filing; that press release is incorporated by reference into the 8-K.

Key Details

• Filing date: March 19, 2026 (Current Report on Form 8-K).
• Reporting period: financial results for the year ended December 31, 2025.
• Item reported: 2.02 (Results of Operations and Financial Condition) — press release furnished as Exhibit 99.1.
• Technical exhibit: Cover page XBRL tags are embedded in the inline XBRL document (Exhibit 104).

Why It Matters
This 8-K signals that Taysha has released its full-year 2025 earnings and business updates; investors should read the furnished press release (Exhibit 99.1) for the company’s reported revenue, operating results, cash position, and any management commentary or guidance. The filing itself is a routine but material disclosure that provides the official notice that the company’s year‑end financial results and recent operational highlights are now public.